These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 32360447)

  • 21. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy.
    Zhang X; Liu C; Gong Q; Zhang S; Zhang D; Lu Z; Wang Y
    J Gastroenterol Hepatol; 2003 Dec; 18(12):1353-7. PubMed ID: 14675262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Relationship between hepatitis B virus YMDD mutation and serum viral DNA loadings].
    Kong LH; Gao SX; Gui YP; Liu WH
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1262-3. PubMed ID: 17715043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers.
    Kim JK; Lee HJ; Lee YJ; Chun JY; Lee IK; Lim YS; Suh DJ; Ko SY; Kim MH; Oh HB
    J Virol Methods; 2008 Apr; 149(1):76-84. PubMed ID: 18291537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of periodic detection of hepatitis B virus YVDD mutation by ultrasensitive real-time amplification refractory mutation system quantitative PCR during lamivudine treatment in patients with chronic hepatitis B.
    Zeng Y; Yang B; Wu Y; Chen J; Shang H; Chen X; Su M; Wu S; Lin J; Ou Q
    J Med Microbiol; 2015 Mar; 64(Pt 3):237-242. PubMed ID: 25596114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.
    Wu F; Wu MJ; Zhuge XL; Zhu SM; Zhu B
    Hepatobiliary Pancreat Dis Int; 2012 Apr; 11(2):172-6. PubMed ID: 22484586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The natural YMDD mutations of hepatitis B virus in Western China.
    Zhao J; Guo Y; Yan Z; Liang P; Zhang J; Liu Y
    Scand J Infect Dis; 2012 Jan; 44(1):44-7. PubMed ID: 21851334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
    Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay.
    Tadokoro K; Suzuki F; Kobayashi M; Yamaguchi T; Nagano M; Egashira T; Kumada H
    J Virol Methods; 2011 Jan; 171(1):67-73. PubMed ID: 20950650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).
    Osiowy C; Villeneuve JP; Heathcote EJ; Giles E; Borlang J
    J Clin Microbiol; 2006 Jun; 44(6):1994-7. PubMed ID: 16757589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-time PCR detection of multiple lamivudine-resistant mutations with displacing probes in a single tube.
    Wen H; Li Q
    J Clin Virol; 2007 Apr; 38(4):334-40. PubMed ID: 17329165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
    Pan XP; Wo JE; Chen Z; Chen F; Liang WF; Liu KZ
    Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Detection of resistance mutations in chronic hepatitis B patients receiving antiviral therapy for over one year].
    Aydoğan S; Ergünay K; Balaban Y; Alp A; Simşek H; Tatar G; Hasçelik G; Us D
    Mikrobiyol Bul; 2013 Jul; 47(3):472-81. PubMed ID: 23971924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
    Arslan U; Ural O; Findik D
    Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of HBV resistance to lamivudine in patients with chronic hepatitis B using Zip nucleic acid probes in Kerman, southeast of Iran.
    Afshar RM; Mollaie HR
    Asian Pac J Cancer Prev; 2012; 13(8):3657-61. PubMed ID: 23098450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
    Mirandola S; Sebastiani G; Rossi C; Velo E; Erne EM; Vario A; Tempesta D; Romualdi C; Campagnolo D; Alberti A
    Antiviral Res; 2012 Dec; 96(3):422-9. PubMed ID: 23026293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultrasensitive amplification refractory mutation system real-time PCR (ARMS RT-PCR) assay for detection of minority hepatitis B virus-resistant strains in the era of personalized medicine.
    Ntziora F; Paraskevis D; Haida C; Manesis E; Papatheodoridis G; Manolakopoulos S; Elefsiniotis I; Karamitros T; Vassilakis A; Hatzakis A
    J Clin Microbiol; 2013 Sep; 51(9):2893-900. PubMed ID: 23804383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants.
    Caccamo L; Romeo R; Rossi G; Maggioni M; Radice F; Lunghi G; Colombo M; Fassati LR
    Transpl Int; 2005 Feb; 18(2):186-92. PubMed ID: 15691271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical evaluation of oligonucleotide microarrays for the detection of HBV mutants associated with lamivudine resistance.
    Chen LY; Huang J; Zhang XP; Qiao P; Zhang W; Yang NM; Liu HJ; Geng YY; Qiu JM; Wang SQ
    Pharmacogenomics; 2005 Oct; 6(7):721-30. PubMed ID: 16207149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.